- Home
- SGMO
as of 12-05-2025 3:46pm EST
$0.50
$0.03
-5.98%
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Chart Type:
Time Range:
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 155.1M | IPO Year: | 2000 |
| Target Price: | $4.71 | AVG Volume (30 days): | 9.3M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.38 - $2.84 | Next Earning Date: | 11-06-2025 |
| Revenue: | $32,875,000 | Revenue Growth: | -37.13% |
| Revenue Growth (this year): | 1.37% | Revenue Growth (next year): | -16.33% |
AI-Powered SGMO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 78.00%
78.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Sangamo Therapeutics Inc. News
SGMO Breaking Stock News: Dive into SGMO Ticker-Specific Updates for Smart Investing
MT Newswires
Sangamo Therapeutics' Potential Small Fiber Neuropathy Pain Treatment Granted Fast-Track Status; Shares up Pre-Bell
📊
AI Sentiment
Positive
6/10
GlobeNewswire
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
📈
AI Sentiment
Highly Positive
8/10
Compare SGMO vs Leading Stocks
See how SGMO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SGMO Sangamo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.